LENZ Therapeutics (LENZ) Current Assets (2020 - 2026)

LENZ Therapeutics (LENZ) has 7 years of Current Assets data on file, last reported at $268.4 million in Q1 2026.

• Quarterly Current Assets rose 35.64% year-over-year to $268.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $268.4 million (up 35.64% YoY) and the FY2025 annual result came in at $301.4 million, up 42.23% from the prior year.
• Current Assets fell to $268.4 million in Q1 2026 per LENZ's latest filing, from $301.4 million in the prior quarter.
• Across five years, Current Assets topped out at $343.8 million in Q1 2022 and bottomed at $67.2 million in Q4 2023.
• The 5-year median for Current Assets is $238.8 million (2023), against an average of $241.7 million.
• The widest annual swing landed in 2023, when Current Assets slumped 75.58%; it then jumped 215.15% in 2024.
• Tracing LENZ's Current Assets over 5 years: stood at $275.4 million in 2022, then tumbled by 75.58% to $67.2 million in 2023, then jumped by 215.15% to $211.9 million in 2024, then soared by 42.23% to $301.4 million in 2025, then declined by 10.96% to $268.4 million in 2026.
• Per Business Quant, the three latest LENZ Current Assets figures stand at $268.4 million (Q1 2026), $301.4 million (Q4 2025), and $207.0 million (Q3 2025).

Peer Comparison